Edesa Biotech, Inc. (EDSA)

Edesa Biotech Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Revenue	-	-	-	-	0.33
Revenue Growth (YoY)	-	-	-	-	-19.97%
Cost of Revenue	-	-	-	-	0.02
Gross Profit	-	-	-	-	0.31
Selling, General & Admin	4.13	4.43	5.04	5.73	3.38
Research & Development	2.88	4.79	13.34	17.95	3.33
Operating Expenses	7.01	9.22	18.37	23.68	6.71
Operating Income	-7.01	-9.22	-18.37	-23.68	-6.4
Interest & Investment Income	0.15	0.29	0.06	0.01	0.04
Currency Exchange Gain (Loss)	-0.02	-0.02	-0.02	-0.01	-0
EBT Excluding Unusual Items	-6.88	-8.95	-18.33	-23.68	-6.36
Other Unusual Items	0.71	0.58	0.78	10.34	-
Pretax Income	-6.17	-8.37	-17.55	-13.34	-6.36
Income Tax Expense	0	0	0	0	0
Net Income	-6.17	-8.37	-17.55	-13.34	-6.36
Net Income to Common	-6.17	-8.37	-17.55	-13.34	-6.36
Shares Outstanding (Basic)	3	3	2	2	1
Shares Outstanding (Diluted)	3	3	2	2	1
Shares Change (YoY)	11.84%	36.37%	21.50%	40.32%	87.63%
EPS (Basic)	-1.93	-2.93	-8.37	-7.73	-5.18
EPS (Diluted)	-1.93	-2.93	-8.37	-7.73	-5.18
Free Cash Flow	-4.89	-6.64	-12.28	-13.67	-4.99
Free Cash Flow Per Share	-1.53	-2.32	-5.86	-7.92	-4.06
Gross Margin	-	-	-	-	94.65%
Operating Margin	-	-	-	-	-1946.72%
Profit Margin	-	-	-	-	-1935.59%
Free Cash Flow Margin	-	-	-	-	-1518.00%
EBITDA	-6.9	-9.12	-18.26	-23.57	-6.35
D&A For EBITDA	0.11	0.11	0.11	0.11	0.06
EBIT	-7.01	-9.22	-18.37	-23.68	-6.4

Source: S&P Capital IQ. Standard template. Financial Sources.